Last $0.03 USD
Change Today -0.0014 / -5.05%
Volume 692.5K
BHRT On Other Exchanges
As of 5:20 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

bioheart inc (BHRT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $0.08
52 Week Low
12/12/13 - $0.0063
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOHEART INC (BHRT)

Related News

No related news articles were found.

bioheart inc (BHRT) Related Businessweek News

No Related Businessweek News Found

bioheart inc (BHRT) Details

Bioheart, Inc., a development stage biotechnology company, focuses on the discovery, development, and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage, and degenerative diseases. Its lead product candidate is MyoCell, a clinical muscle-derived cell therapy that has completed Phase II-a study and populates regions of scar tissue within a patient’s heart with new living cells for improving cardiac function in chronic heart failure patients. The company also develops MyoCell SDF-1, an autologous cell therapy treatment for severe chronic damage to the heart and cells modified to express angiogenic factors; AdipoCell, an adipose cell therapy treatment for the management of progressive heart failure; and MyoCath, a disposable endoventricular catheter used for the delivery of biologic solutions to the myocardium. In addition, its preclinical stage product candidates include MyoCath II, which provides multidirectional cell injection, as well as is used for the delivery of biologic solutions to the myocardium. Bioheart, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

4 Employees
Last Reported Date: 05/9/14
Founded in 1999

bioheart inc (BHRT) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $766.7K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $284.2K
Compensation as of Fiscal Year 2013.

bioheart inc (BHRT) Key Developments

Bioheart, Inc. Announces Combination Stem Cell Treatment

Bioheart, Inc. announced that it has completed the combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell(TM) or adipose derived stem cells and MyoCell(R) or muscle derived stem cells. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation. The cells were delivered directly into the damaged areas of the heart using the MyoCath(R) Catheter.

Bioheart, Inc. Announces Clinical Trials in India

Bioheart, Inc. announced that they have begun two clinical trials in India including the first ever combination stem cell trial in the world. The first cardiac patient has successfully been enrolled and treated in India using AdipoCell or adipose derived stem cells. The second trial will involve the combination of AdipoCell and MyoCell or muscle derived stem cells for congestive heart failure patients. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation.

Bioheart, Inc. Enters into Joint Venture with Dr. Walter Bell of South Africa

Bioheart, Inc. announced that it has entered into a joint venture with Dr. Walter Bell of South Africa. Under this new agreement, the facilities in South Africa will be expanded to provide cell culture expansion and cryopreservation to local patients. Bioheart can multiply and preserve an individual's cells in sub-zero temperatures for future treatments as required. Bioheart's partnership will establish a critical relationship with the South African government and the joint venture will work closely with the Ministry of Health to make Bioheart protocols part of the standard of care for patients in South Africa and neighboring countries. Bioheart will provide the necessary training and expertise to transfer Bioheart therapies to the new facility. Bioheart will assume 49% ownership of the new entity. Dr. Walter Bell and his team will offer these therapies to the more than 51 million people living in South Africa as well as being a premier site for medical tourism.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BHRT:US $0.03 USD -0.0014

BHRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $74.97 USD +0.28
BioTime Inc $2.52 USD -0.02
Celgene Corp $86.65 USD -0.50
International Stem Cell Corp $0.12 USD +0.005
StemCells Inc $1.61 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation BHRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOHEART INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at